OTCMKTS:STDAF - STADA Arzneimittel Aktiengesellschaft Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$110.42
+0.30 (1.20%)

This chart shows the closing price for STDAF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New STADA Arzneimittel Aktiengesellschaft Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STDAF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STDAF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for STADA Arzneimittel Aktiengesellschaft in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $110.42.

This chart shows the closing price for STDAF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in STADA Arzneimittel Aktiengesellschaft. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/6/2018DZ BankReiterated RatingSell
1/2/2018Nord/LBReiterated RatingSell
1/1/2018DZ BankReiterated RatingSell
12/27/2017Nord/LBReiterated RatingSell
12/26/2017DZ BankReiterated RatingSell
12/20/2017DZ BankReiterated RatingSell
11/9/2017DZ BankReiterated RatingSell
8/18/2017DZ BankReiterated RatingSell
7/10/2017DZ BankReiterated RatingSell
6/28/2017DZ BankReiterated RatingNeutral
6/22/2017DZ BankReiterated RatingSell
6/8/2017DZ BankReiterated RatingSell
5/29/2017DZ BankReiterated RatingSell
(Data available from 5/22/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
STADA Arzneimittel Aktiengesellschaft logo
STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products. It operates through the Generics and Branded Products segments. The Generics segment produces and distributes generic drugs. The Branded Products segment sells branded healthcare products and medicines. Its brands include Zoflora, Grippostad, Nizoral, and Shampoo & Ladival. The company was founded on March 14, 1895 and is headquartered in Bad Vilbel, Germany.
Read More

Today's Range

Now: $110.42
Low: $110.42
High: $110.42

50 Day Range

MA: $110.42
Low: $110.42
High: $110.42

52 Week Range

Now: $110.42
Low: $75.15
High: $115.00

Volume

N/A

Average Volume

N/A

Market Capitalization

$6.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Frequently Asked Questions

What sell-side analysts currently cover shares of STADA Arzneimittel Aktiengesellschaft?

The following sell-side analysts have issued stock ratings on STADA Arzneimittel Aktiengesellschaft in the last twelve months:
View the latest analyst ratings for STDAF.

What is the current price target for STADA Arzneimittel Aktiengesellschaft?

0 Wall Street analysts have set twelve-month price targets for STADA Arzneimittel Aktiengesellschaft in the last year.
View the latest price targets for STDAF.

What is the current consensus analyst rating for STADA Arzneimittel Aktiengesellschaft?

STADA Arzneimittel Aktiengesellschaft currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for STDAF.

How do I contact STADA Arzneimittel Aktiengesellschaft's investor relations team?

STADA Arzneimittel Aktiengesellschaft's physical mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company's listed phone number is (496) 101-6030 and its investor relations email address is [email protected] The official website for STADA Arzneimittel Aktiengesellschaft is www.stada.com. Learn More about contacing STADA Arzneimittel Aktiengesellschaft investor relations.